Amended Statement of Ownership (sc 13g/a)
April 16 2015 - 4:46PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act
of 1934
(Amendment No. 6)*
ALBANY MOLECULAR RESEARCH, INC.
(Name of Issuer)
COMMON STOCK, $0.01 PAR VALUE
(Title of Class of Securities)
012423109
(CUSIP Number)
DECEMBER 31, 2014
(Date of Event Which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant
to which this Schedule is filed:
¨
Rule 13d-1(b)
x
Rule 13d-1(c)
¨
Rule 13d-1(d)
*The remainder of this cover page shall be filled out for
a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures provided in a prior cover page. The information required in
the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes ).
1. |
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES
ONLY)
CONSTANCE M. D’AMBRA
|
2. |
CHECK THE APPROPRIATE BOX IF
A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)
¨
(b)
¨
|
3. |
SEC USE ONLY
|
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
UNITED STATES
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH |
5. |
SOLE VOTING POWER —0—
|
|
6. |
SHARED VOTING POWER 2,535,818 (1)
|
|
7. |
SOLE DISPOSITIVE POWER —0—
|
|
8. |
SHARED DISPOSITIVE POWER 2,535,818 (1)
|
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
2,535,818 (1)
|
10. |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) x
(1)
|
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.8% (2)
|
12. |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
|
(1) Mrs. D'Ambra jointly owns 2,535,818
shares with her spouse, Dr. Thomas E. D’Ambra. Dr. and Mrs. D'Ambra may be deemed to beneficially own an additional 375,000
shares, which are held by the Thomas D’Ambra SLAT Trust (the "Trust Shares"). The trustee of the Thomas D’Ambra
SLAT trust is Dr. and Mrs. D’Ambra’s son, Geoffrey D’Ambra. Mrs. D'Ambra disclaims beneficial ownership of the
Trust Shares, and this report shall not be deemed an admission that she is the beneficial owner of the Trust Shares, except to
the extent of her pecuniary interest, if any, in the Trust Shares.
|
(2) |
Based on 32,632,940 shares of Common Stock outstanding as of December 31, 2014. |
Item 1
Albany Molecular Research, Inc.
(the “Issuer”)
|
(b). |
Address of Issuer’s Principal Executive Offices: |
26 Corporate Circle, Albany,
NY 12203
Item 2
|
(a). |
Name of Person Filing: |
Constance M. D’Ambra
|
(b). |
Address of Principal Business Office or, if None, Residence: |
26 Corporate Circle, Albany,
NY 12203
United States
|
(d). |
Title of Class of Securities: |
Common Stock, $0.01 par value
012423109
|
(a) |
Amount beneficially owned: 2,535,818 (1) |
|
(b) |
Percent of class: 7.8% (2) |
|
(c) |
Number of shares as to which such person has: |
|
(i) |
Sole power to vote or to direct the vote: -0- |
|
(ii) |
Shared power to vote or to direct the vote : 2,535,818 (1) |
|
(iii) |
Sole power to dispose or to direct the disposition of: -0- |
|
(iv) |
Shared power to dispose or to direct the disposition of: 2,535,818 (1) |
(1) Mrs. D'Ambra jointly owns 2,535,818
shares with her spouse, Dr. Thomas E. D’Ambra. Dr. and Mrs. D'Ambra may be deemed to beneficially own an additional 375,000
shares, which are held by the Thomas D’Ambra SLAT Trust (the "Trust Shares"). The trustee of the Thomas D’Ambra
SLAT trust is Dr. and Mrs. D’Ambra’s son, Geoffrey D’Ambra. Mrs. D'Ambra disclaims beneficial ownership of the
Trust Shares, and this report shall not be deemed an admission that she is the beneficial owner of the Trust Shares, except to
the extent of her pecuniary interest, if any, in the Trust Shares.
(2) Based on 32,632,940 shares of Common
Stock outstanding as of December 31, 2014.
Item 5. |
Ownership of Five Percent or Less of a Class. |
N/A
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person. |
N/A
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. |
N/A
Item 8. |
Identification and Classification of Members of the Group. |
N/A
Item 9. |
Notice of Dissolution of Group. |
N/A
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with
or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is true, complete and correct.
|
April 16, 2015 |
|
Date |
|
|
|
/s/ Constance M. D’Ambra |
|
Signature |
|
|
|
Constance M. D’Ambra |
|
Name |
Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Sep 2023 to Sep 2024